Injecting drug use increases the risk of death in HIV patients on antiretroviral therapy in Vietnam

Bibliographic Data

ID19444152
AuthorsLucia Araujo-Chaveron (0000-0002-2110-6088, EHESP French School of Public Health, Paris, France), Tram Thi Phuong Pham (National Institute Of Hygiene And Epidemiology), Binh Thanh Nguyen (0000-0002-5925-5273, National Institute Of Hygiene And Epidemiology), Tram Hong Tran (National Institute Of Hygiene And Epidemiology), Nhung Thi Hong Le (National Institute Of Hygiene And Epidemiology), Phạm Hồng Thắng (0000-0002-9618-681X, National Institute Of Hygiene And Epidemiology), Thang Hong Pham (National Institute Of Hygiene And Epidemiology), Khanh Phuong Ngo (National Institute Of Hygiene And Epidemiology), Ha Thi Tong (National Institute Of Hygiene And Epidemiology), Huong Thi Thu Phan (Ministry of Health, Vietnam Administration of HIV/AIDS Control (VAAC), Hanoi, Vietnam), Mohand Ait-Ahmed (Institut Pasteur, Center for Translational Research, Université de Paris, Paris, France), Mohand Ait‐Ahmed (Institut Pasteur), Thanh An Nguyen (0000-0003-3948-0542, National Institute Of Hygiene And Epidemiology), Nguyen Anh Tuan (0009-0006-0096-3765, National Institute Of Hygiene And Epidemiology), Tuan Anh Nguyen (0009-0003-0449-8862), Fabien Taieb (0000-0002-0941-2859, Institut Pasteur, Center for Translational Research, Université de Paris, Paris, France), Yoann Madec (0000-0002-6201-1261, Institut Pasteur, Epidemiology of Emerging Diseases, Université de Paris, Paris, France, corresponding author)
Year2024
Volume36
Issue5
Pages631-640
Publication date2024-05-03
Open AccessNo
TypeARTICLE
VenueAIDS Care (JOURNAL)
Journal identifiersISSN: 0954-0121 • E-ISSN: 1360-0451
PublisherInforma UK Limited (PUBLISHER • GB)
DOI10.1080/09540121.2023.2224549
PMID37339000
OpenAlexW4381381112
LanguageEN
Citations received1
References cited34

The Human Immunodeficiency Virus (HIV) epidemic remains a major public health issue worldwide. In Vietnam, the HIV epidemic is essentially driven by people who inject drugs (PWID). This study aims to compare mortality and loss to follow-up (LTFU) between PWID and other patients. From June 2017 to April 2018, HIV-infected adults were enrolled in a prospective cohort from time of ART initiation in six provinces of North Vietnam. The end date was July 2020. Mortality and LTFU were described using competing-risk survival models. Factors associated with mortality and with LTFU were identified using Cox models with a competing-risk approach. Of the 578 participants, 261 (45.2%) were PWID and almost exclusively male. 49 patients died, corresponding to a mortality rate (95% confidence interval (CI)) of 3.7 (2.8–4.9) per 100 person-months, and 79 were lost to follow-up, corresponding to a rate (95% CI) of 6.0 (4.8–7.4) per 100 person-months. PWID were at higher risk of death but not of LTFU. Overall, LTFU was high in both groups. Latecomers to clinical visits were more at risk of both death and LTFU. Therefore, this should be a warning to clinical teams and preventive actions taken in these patients.Trial registration: ClinicalTrials.gov identifier: NCT03249493

Antiretroviral therapy · Cohort · Cohort study · Confidence interval · Family medicine · Mortality rate · Proportional hazards model · Prospective cohort study · Viral load · Demography · HIV Research and Treatment · HIV, Drug Use, Sexual Risk · HIV/AIDS Research and Interventions · Medicine · Internal Medicine · Pediatrics

Tools

Open DOI